Navigation Links
Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation

Great Neck, N.Y., Jan. 18 /PRNewswire/ -- On January 17, 2008, the law firms of Parker Waichman Alonso LLP, Becnel Law Firm, LLC, Douglas & London P.C., Levin Simes Kaiser and Gornick LLP, Bailey Perrin Bailey LLP and Weitz & Luxenberg, P.C., have filed over a Billion ($1,000,000,000) Dollar Class Action lawsuit claiming refunds for purchasers of Vytorin, in Federal District Court, Eastern District of New York, Docket #08-258 before The Honorable Carol Bagley Amon, Judge of the United States Eastern District Court of New York, against Merck & Co., Inc. and Schering-Plough Corporation. The class action seeks, in part, refunds to individuals who were prescribed and purchased the popular cholesterol statin drug, Vytorin(R). Vytorin(R) is a single pill combination of two drugs, Zocor and Zetia, (ezetimibe plus simvastatin).

The lawsuit alleges that Merck & Co., Inc. and Schering-Plough Corporation, the manufacturers of the prescription drug, Vytorin(R), made misrepresentations and withheld significant information in its approval submissions and filings with the Federal Drug Administration. It is also alleged that misrepresentations were made to the general public through marketing efforts as to the effectiveness of the drug. In reality, studies have shown that it is no better than other available drugs on the market in lowering cholesterol.

The above law firms have been contacted and retained by many individuals, including the proposed class representative, who have been prescribed and used Vytorin(R) and who are seeking refunds for their prescriptions.

If you or someone you know was prescribed and purchased, Vytorin(R), please contact our office by visiting our website at Free case evaluations are also available by calling Parker Waichman Alonso LLP at 1-800-LAW-INFO (1-800-529-4636).

SOURCE Parker Waichman Alonso LLP
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Keppra XR(TM) Extended-Release Tablets Filed with the FDA
2. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
3. Roche Diagnostics HIV Viral Load Test Used in Clinical Trials for Isentress, a New Class of HIV Drug
4. Coley Pharmaceutical Group Diversifies Pipeline with First-in-Class TLR Antagonist for the Treatment of Systemic Lupus Erythematosus
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
7. Study Results Reveal alli(R) Patient Satisfaction Linked to Weight Loss Achieved; Not Treatment Effects
8. AIDS Action Council Statement on World AIDS Day 2007: Leadership Needed for a National Strategy to Stop the AIDS Epidemic
9. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
10. Radiesse Provides Greater Patient Satisfaction Than Either Juvederm or Perlane as Reported in a 205-Patient Clinical Trial Published in the Journal of Dermatologic Surgery
11. Study Linking Increased Risk of Death to Severe Psoriasis a Call to Action
Post Your Comments:
(Date:12/1/2015)... Dec. 1, 2015  Lexicon Pharmaceuticals, Inc. ... top-line data from its TELECAST Phase 3 ... treating carcinoid syndrome in cancer patients with ... benefit observed in its pivotal TELESTAR study.  ... companion to TELESTAR primarily to provide additional ...
(Date:12/1/2015)... , Dec. 1, 2015  ImmunoCellular Therapeutics, ... Andrew Gengos , President and Chief ... on December 3, 2015. Mr. Gengos plans ... registrational program in patients with newly diagnosed ... TIME:    12:15p.m. ET/9:15a.m. PT LINK: ...
(Date:12/1/2015)... and UPPSALA, Sweden , December ... been selected by the International Breast Cancer Study Group (IBCSG, ... (BIG, Brussels ) to be part of ... palbociclib, a promising new cancer drug.  --> ... women with advanced breast cancer being treated with anti-hormonal therapy ...
Breaking Medicine Technology:
(Date:12/1/2015)... PA (PRWEB) , ... December 01, 2015 , ... ... imaging facilities, radiographic technicians must mark the film for accurate interpretation by the ... track of. Fortunately, an inventor from Sacramento, Calif., has found a way to ...
(Date:12/1/2015)... ... 2015 , ... McLean, VA., December 1, 2015 - Octo ... sprint agile development contract to support the National Geospatial-Intelligence Agency's (NGA) IT Services ... engineering, infrastructure, as well as operations and sustainment support to the NGA’s Agile ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech , ... membership and leadership since 2008. Gary Bruce, President of PartnerTech North America, currently ... spent a significant amount of time in Sweden since joining PartnerTech based in ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... Center Enterprise Authorized Technology Provider (ATP) status from Cisco. This designation recognizes Tympani ... support Cisco Unified Contact Center solutions targeted to the high-end enterprise contact center ...
(Date:11/30/2015)... NY (PRWEB) , ... December 01, 2015 , ... ... honors Christina Colon as a 2015-2016 inductee into its VIP Woman ... in pharmacy. NAPW is the nation’s leading networking organization exclusively for professional women, ...
Breaking Medicine News(10 mins):